dc.contributor.author
Dame, Christof
dc.contributor.author
Sciesielski, Lina K.
dc.contributor.author
Rau, Carolin
dc.contributor.author
Badur, Chiara-Aiyleen
dc.contributor.author
Bührer, Christoph
dc.date.accessioned
2022-12-22T07:42:21Z
dc.date.available
2022-12-22T07:42:21Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/37125
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-36838
dc.description.abstract
In this case-control study, the erythropoietin (EPO) promoter variant s1617640, linked to high intravitreal EPO concentrations and increased risk of diabetic retinopathy, was not associated with severe retinopathy of prematurity. This finding was observed both in infants with and without recombinant EPO administration.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
rhEpo treatment
en
dc.subject
SNP risk allele
en
dc.subject
retinopathy of prematurity (ROP)
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
The Erythropoietin Promoter Variant rs1617640 Is Not Associated with Severe Retinopathy of Prematurity, Independent of Treatment with Erythropoietin
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1016/j.jpeds.2018.03.014
dcterms.bibliographicCitation.journaltitle
The Journal of Pediatrics
dcterms.bibliographicCitation.originalpublishername
Elsevier
dcterms.bibliographicCitation.pagestart
256
dcterms.bibliographicCitation.pageend
259
dcterms.bibliographicCitation.volume
199
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.note.author
Original article first published: 2018-05-03.
en
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
29731355
dcterms.isPartOf.eissn
1097-6833
